Search Within

Saad Zafar Usmani

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (24)
  2. Journal Article (9)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Department of Pathology and Laboratory Medicine (35)
  2. Center for Hematologic Malignancies (34)
  3. Department of Medicine (34)
  4. Hematologic Malignancies, Division of (34)
  5. Myeloma (34)
  6. Hematologic Malignancies Research (33)

More Groups

People
  1. Alexander Lesokhin (32)
  2. Neha Korde (27)
  3. David Chung (25)
  4. Heather Landau (25)
  5. Kylee Maclachlan (25)
  6. Sham Mailankody (25)

More People

Years
  1. 2025 (2)
  2. 2024 (8)
  3. 2023 (15)
  4. 2022 (10)
Publications
  1. Blood (15)
  2. Clinical Lymphoma, Myeloma and Leukemia (11)
  3. Blood Advances (2)
  4. Journal of Clinical Oncology (2)
  5. New England Journal of Medicine (2)
  6. Cancer Cell (1)

More Publications

Publishers
  1. American Society of Hematology (17)
  2. Elsevier Inc. (11)
  3. American Society of Clinical Oncology (2)
  4. Massachusetts Medical Society (2)
  5. Cell Press (1)
  6. Nature Research (1)

More Publishers

Results (35)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
    Research Letter

    Stuver, R.; Shah, G. L.; Korde, N. S.; Roeker, L. E.; Mato, A. R.; Batlevi, C. L.; Chung, D. J.; Doddi, S.; Falchi, L.; Gyurkocza, B.; more...
    Cancer Cell (2022)

    Fulltext@MSK | Save